Sugammadex, a modified γ-cyclodextrin, is the first selective relaxant binding agent. Sugammadex forms very tight complexes in a 1:1 ratio with steroidal neuromuscular blocking agents (rocuronium ...

The case involves Merck’s U.S. Patent No. RE44,733 (“the RE’733 patent”), which includes claims directed to “sugammadex,” the active ingredient in Merck’s BRIDION® drug for ...

The patent at issue is listed in the Orange Book for Merck’s BRIDION® (sugammadex) product, which is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and ...